Related Experiment Video
Updated: Oct 8, 2025
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Immunotherapy for Melanoma
Justin T Moyers1,2, Isabella C Glitza Oliva3
1Department of Investigational Cancer Therapeutics, UT MD Anderson Cancer Center, Houston, TX, USA.
Abstract:
Melanoma is the leading cause of death from skin cancer and is responsible for over 7000 deaths in the USA each year alone. For many decades, limited treatment options were available for patients with metastatic melanoma; however, over the last decade, a new era in treatment dawned for oncologists and their patients. Targeted therapy with BRAF and MEK inhibitors represents an important cornerstone in the treatment of metastatic melanoma; however, this chapter carefully reviews the past and current therapy options available, with a significant focus on immunotherapy-based approaches. In addition, we provide an overview of the results of recent advances in the adjuvant setting for patients with resected stage III and stage IV melanoma, as well as in patients with melanoma brain metastases. Finally, we provide a brief overview of the current research efforts in the field of immuno-oncology for melanoma.
Insights
Metastatic melanoma treatment has advanced significantly, moving beyond limited options to include targeted therapies like BRAF and MEK inhibitors. Immunotherapy and recent adjuvant treatments offer new hope for patients with advanced melanoma.
Area of Science:
- Oncology
- Dermatology
- Immunology
Background:
- Melanoma is a leading cause of cancer death, with limited options for metastatic disease historically.
- Recent decades have seen major advancements in melanoma treatment strategies.
- Targeted therapies and immunotherapy have transformed patient care.
Purpose of the Study:
- To review past and current therapeutic options for metastatic melanoma.
- To highlight the significant role of immunotherapy in melanoma treatment.
- To discuss recent advances in adjuvant therapy and for melanoma brain metastases.
Main Methods:
- Review of existing literature on melanoma treatment.
- Analysis of clinical trial data for targeted therapies and immunotherapies.
- Examination of outcomes in adjuvant settings and for brain metastases.
Main Results:
- Targeted therapy (BRAF and MEK inhibitors) is a cornerstone for metastatic melanoma.
- Immunotherapy-based approaches have shown significant promise and efficacy.
- Recent advances in adjuvant settings improve outcomes for resected stage III/IV melanoma.
- Effective management strategies for melanoma brain metastases are emerging.
Conclusions:
- The treatment landscape for melanoma has dramatically improved with targeted therapies and immunotherapy.
- Adjuvant treatments and management of brain metastases represent key areas of progress.
- Ongoing research in immuno-oncology continues to drive innovation in melanoma care.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...